CYTOIMMUNE THERAPEUTICS LLC has a total of 14 patent applications. Its first patent ever was published in 2016. It filed its patents most often in Australia, China and EPO (European Patent Office). Its main competitors in its focus markets biotechnology and pharmaceuticals are LENTIGEN TECH INC, LENTIGEN TECHNOLOGY INC and INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 3 | |
#2 | China | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | Republic of Korea | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | Canada | 1 | |
#7 | Hong Kong | 1 | |
#8 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Yu Jianhua | 14 |
#2 | Caligiuri Michael | 13 |
#3 | Devine Steven | 8 |
#4 | Michael Caligiuri | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020010284A1 | Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1 | |
AU2016326721A1 | FLT3 directed car cells for immunotherapy | |
AU2016246457A1 | EGFR-directed car therapy for glioblastoma |